{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:02:17Z","timestamp":1791259337671,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008482","name":"Association of Public Health Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["75R60220R00023"],"award-info":[{"award-number":["75R60220R00023"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.gim.2022.10.012","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T09:56:04Z","timestamp":1669715764000},"page":"100330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-3297","authenticated-orcid":false,"given":"Margie A.","family":"Ream","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelili","family":"Ojodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Ros\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Comeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tanksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2022.10.012_bib1","author":"Kemper"},{"issue":"2","key":"10.1016\/j.gim.2022.10.012_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1399-0004.1998.tb02654.x","article-title":"Brother\/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation","volume":"53","author":"Sukegawa","year":"1998","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.gim.2022.10.012_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of mucopolysaccharidoses update","volume":"11","author":"\u00c7elik","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","article-title":"Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities","volume":"16","author":"Puckett","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.10.012_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/ijns6040079","article-title":"Validation and implementation of a highly sensitive and efficient newborn screening assay for mucopolysaccharidosis type II","volume":"6","author":"Bilyeu","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns6030073","article-title":"Newborn screening for mucopolysaccharidosis type II in Illinois: an update","volume":"6","author":"Burton","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"2","key":"10.1016\/j.gim.2022.10.012_bib7","first-page":"S91","article-title":"Clinical characteristics of patients with neuronopathic and non-neuronopathic mucopolysaccharidosis type II: data from the Hunter Outcome Survey","volume":"126","author":"Lau","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajmg.c.31915","article-title":"Genotype-phenotype studies in a large cohort of Brazilian patients with Hunter syndrome","volume":"187","author":"Josahkian","year":"2021","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"10.1016\/j.gim.2022.10.012_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A\u00a0phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.gim.2022.10.012_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A\u00a0phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2022.10.012_bib12","first-page":"2","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.gim.2022.10.012_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.gim.2022.10.012_bib14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride","year":"2020","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2022.10.012_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10545-012-9533-7","article-title":"Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations","volume":"36","author":"Pollard","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.10.012_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2009.05.006","article-title":"Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation","volume":"98","author":"Araya","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.gim.2022.10.012_bib18","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"10","key":"10.1016\/j.gim.2022.10.012_bib20","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.gim.2022.10.012_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3476(96)70202-0","article-title":"Bone marrow transplantation in Hunter syndrome","volume":"129","author":"McKinnis","year":"1996","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.gim.2022.10.012_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.gim.2022.10.012_bib24","first-page":"184","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gim.2022.10.012_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2014.11.002","article-title":"Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation","volume":"114","author":"Tanjuakio","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1373\/clinchem.2006.077263","article-title":"Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease)","volume":"53","author":"Wang","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.gim.2022.10.012_bib27","first-page":"23","article-title":"Newborn screening for Hunter disease: a small-scale feasibility study","volume":"14","author":"Ruijter","year":"2014","journal-title":"JIMD Rep"},{"key":"10.1016\/j.gim.2022.10.012_bib28","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.gim.2022.10.012_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib30","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib31","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep"},{"key":"10.1016\/j.gim.2022.10.012_bib32","article-title":"Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair","volume":"30","author":"Grant","year":"2022","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2022.10.012_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.gim.2022.10.012_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/GIM.0b013e31816b64f9","article-title":"Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services\u2019 Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children","volume":"10","author":"Kemper","year":"2008","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.gim.2022.10.012_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/GIM.0b013e3182209f09","article-title":"What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services\u2019 Advisory Committee on Heritable Disorders in Newborns and Children","volume":"13","author":"Hinton","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2022.10.012_bib36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpeds.2020.05.005","article-title":"Treatment discontinuation by 3 years after levothyroxine initiation among children diagnosed with congenital hypothyroidism","volume":"223","author":"Kemper","year":"2020","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.gim.2022.10.012_bib37","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0904","article-title":"Ensuring the life-span benefits of newborn screening","volume":"144","author":"Kemper","year":"2019","journal-title":"Pediatrics"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022009984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:56:12Z","timestamp":1761098172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022009984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1098360022009984"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.012","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100330"}}